Prof Stephen Johnston speaks to ecancer in an online interview for the virtual ESMO 2020 meeting about the results from the monarchE trial. The phase III trial used abemaciclib plus endocrine therapy to treat patients with high-risk HR positive , HER2 negative early breast cancer in the adjuvant setting.
Prof Johnston reports that the addition of abemaciclib to endocrine therapy results in a reduction of the risk of developing invasive disease recurrence. He explains why these results are clinically meaningful, and comments that if this drug becomes approved he is hopeful that it will become the standard of care for these high-risk patients.
Read related news here.
Read related article here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.